On 31 May 2024, Regeneron and Sanofi announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Dupixent® (dupilumab) as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD).
This comes after the FDA accepted Dupixent® for priority review for the same indication in February 2024. The target action date for the FDA decision was 27 June 2024 but, on 31 May 2024, was revised to 27 September 2024.